Navigation Links
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
Date:7/21/2008

ved the median progression-free survival time from 13.5 months (control arm) to 37 months (p<0.0001).

The primary investigators of the study concluded that Zevalin consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma is highly effective, resulting in a total complete response (CR + CRu) rate of 87 percent and prolongation of median progression-free survival (PFS) by approximately two years, with a toxicity profile comparable to that seen with Zevalin's use in approved indications. Zevalin-treated patients had reversible Grade 3 or 4 hematologic side effects including neutropenia in 67 percent, thrombocytopenia in 61 percent, and anemia in 3 percent. Nonhematologic toxicities were 24% Grade 3, 5% Grade 4, and Grade 3/4 infection was 8%.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is indicated under accelerated approval for the treatment of relapsed or refractory, rituximab-nave, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic t
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
5. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
6. APIC Conference to Discuss MRSA Elimination
7. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
8. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
9. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... and SPARTANBURG, South Carolina , ... Research Network and Molecular Health have announced a collaboration ... diagnostic decision support to the majority of cancer patients ... Network will collaborate with Molecular Health to harness the ... identify cohorts from hundreds of thousands of patients to ...
(Date:5/29/2015)... 2015 Research and Markets ... the "Surgical/Operating Microscopes Market by Application & ... report to their offering.      (Logo: ... is poised to reach $806.6 million by 2020 ... of 12.3% from 2015 to 2020. , ,Major ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... American Association of Cancer Research (AACR) Advances ... potential for its lead product candidate VAL-083 ...
Breaking Medicine Technology:New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... Nov. 28, 2011 The most common poisons that threaten ... acetaminophen, antidepressants, and ADHD medications. Any medication, even those prescribed ... cats that might eat whatever they find. For ... Program and the American Veterinary Medical Association (AVMA) ...
... & Johnson (NYSE: JNJ ) will participate in the ... Nov. 29 th at The New York Palace, New York, ... session scheduled at 8:00 a.m. (Eastern Time). The ... accessing the Johnson & Johnson website at www.investor.jnj.com . ...
Cached Medicine Technology:Sea Grant and AVMA Join Forces to Raise Awareness on Medicine Disposal 2
(Date:5/29/2015)... The Recovery Village at Palmer ... co-occurring mental health treatment facility, will host a ... general public on June 1st, and will begin ... at Palmer Lake will offer affordable detox, residential, ... and evidence-based therapies, in a luxurious setting designed ...
(Date:5/29/2015)... 2015 Red Hot & Blue Restaurants ... Hot & Blue restaurant at 525 New Waverly Place in ... 2015. “The Red Hot & Blue Restaurant was previously located ... we have moved to a new location in the center,” ... of all the activities on the Promenade–with outdoor seating and ...
(Date:5/29/2015)... May 29, 2015 A group of doctors ... joined the national effort to teach this “new math” to ... U.S. have been “sickened” by the recent implementation of Common ... or hate it, Common Core is now a reality in ... Parents are now seeking ways to improve common core ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw Elements ... importance of proper sun protection. The print component of ... circulation of approximately 250,000 copies and an estimated readership ... through a vast social media strategy, and across a ... explore the digital version of the campaign, click ...
(Date:5/29/2015)... 29, 2015 Healthpointe is now ... specialists, physical therapy, and injections , For patients ... and/or lower back pain, Healthpointe has a team ... herniated discs, disc protrusions and other causes of ... Healthpointe’s team of renowned surgeons are now treating ...
Breaking Medicine News(10 mins):Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:Doctors Discover a Cure for the Common Core 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3
... should be made aware, researcher says , , WEDNESDAY, ... twins, those conceived through assisted reproductive technology (ART) are ... intensive care, finds a new study. , Researchers analyzed ... Western Australia between 1994 and 2000. , "We found ...
... Outlines Possible Ways to Improve CBO Modeling and ... a Partnership to Fight Chronic Disease policy briefing ... O,Grady, Ph.D., and James C. Capretta, M.A., released ... and other Chronic Diseases: The Current Context and ...
... Mercy Hospital Indicator of Demand for Well-Priced New ... May 21 Despite numerous negative earnings announcements, ... equipment appears to be robust during the current ... new and refurbished ultrasound solutions, reported a 118 ...
... America, Inc. (OTC Bulletin Board: CPCF.OB), announced today the ... for specific application to the MedClose(TM) VCS. CPC ... MedClose(TM) VCS, which is an internal puncture-closing system for ... In addition, CPC is focused on the development of ...
... Health, Inc. (Nasdaq: GHDX ) today announced ... at the American Society of Clinical Oncology (ASCO) Annual ... at the Orange County Convention Center in Orlando, Florida. ... DX(R) breast cancer test, which is clinically validated to ...
... Company Reports Improved Operating Results, Strengthened Balance SheetTo ... 11 a.m. Eastern Time Today SANTA MONICA, Calif., ... Bulletin Board: CBAI), the umbilical cord blood stem ... bringing the life saving potential of stem cells ...
Cached Medicine News:Health News:Fertility Treatment Twins More at Risk for Hospitalizations 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:MedPro Imaging Reports 118 Percent Growth For First Quarter 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3Health News:Cord Blood America, Inc. Announces 2009 First Quarter Results 2Health News:Cord Blood America, Inc. Announces 2009 First Quarter Results 3Health News:Cord Blood America, Inc. Announces 2009 First Quarter Results 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: